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Endothelial cells, the cells that line blood vessels, become activated during development to 
sprout and form new vessels in a process termed angiogenesis. During development, 
sprouting angiogenesis is robust and is the main driving force behind vascularization of new 
tissues in the embryo. In contrast, endothelial cells are mainly quiescent in the adult and only 
become reactivated during physiological or pathological angiogenesis. The bone 
morphogenetic protein (BMP) pathway has been shown to be a pro-angiogenic cue. During 
postnatal retinal development, BMP receptors are expressed in the retinal vasculature and 
BMP ligands are expressed throughout the retina. Here, we show that deletion of BMP 
receptors, Alk1, Alk2, Alk3, and BMPR2 affect sprouting angiogenesis during development. 
Endothelial specific deletion of Alk2, Alk3, and BMPR2 resulted in decreased sprouting at 
the vascular front as well as branching in the vascular plexus, whereas deletion of Alk1 
resulted in increased sprouting. These data point to a requirement of BMP signaling for 
proper patterning of the retinal vasculature during development. We also analyzed tortuous 
microvessels, abnormal vessels that arise during the wound healing process. Tortuous vessels 
are observed in many diseases, most notably cancer and diabetes. However, the causes and 
consequences of these abnormal vessels have not been elucidated. Here, we use intravital, 
high-resolution imaging to examine the formation, resolution, and sprouting of tortuous 
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microvessels during wound healing. We found that tortuous microvessels are mainly located 
100-300 µm from the wound center and that tortuous microvessels resolved by becoming 
normal again. Additionally, using fluorescent, microcarrier beads we found that beads 
became stuck in tortuous microvessels suggesting differences in flow. The shapes of 
endothelial cells within tortuous microvessels are round, indicative of activated cells, and 
exhibit sprout initiations at a higher frequency than normal vessels. Thus, we highlight an 
important, undiscovered feature of tortuous microvessels, sprouting, that can be used as a 
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Chapter 1: General Introduction 
 
1.1 Sprouting angiogenesis  
My research projects have focused on sprouting angiogenesis and how sprouting is affected 
in different vascular beds in normal and mutant backgrounds. This section describes the 
processes involved in blood vessel development and signaling pathways that are major 
contributors. 
 
Blood Vessel Formation: vasculogenesis and angiogenesis 
The circulatory system is the first functional organ system established in the 
vertebrate embryo, and it consists of blood vessels which transport nutrients and oxygen to 
tissues and provide conduits for waste removal [1-3] . Blood vessels are formed through two 
main processes: vasculogenesis and angiogenesis. Angioblasts, derived from mesoderm cells, 
differentiate into endothelial cells, the cells that line blood vessels, starting at embryonic day 
(E) 7.5.  During this time, angioblasts fuse and coalesce to form blood vessel tubes in a 
process termed vasculogenesis [4]. The tubes become arranged in a primitive vascular plexus 
that subsequently grow into a complex hierarchy of blood vessels, including arteries, veins, 
and capillaries, through a process termed angiogenesis [5]. Angiogenesis is the formation of 
new blood vessels from pre-existing vessels, and can occur through vessel sprouting, 
remodeling, pruning, or intussusception [5, 6]. This chapter will focus on sprouting 
angiogenesis which is defined as an endothelial cell budding from its parent vessel to initiate 
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a new vessel. The mechanisms and processes involved in sprouting will be described in detail 
in the following section. 
 
Signaling pathways regulating angiogenesis 
One of the main signaling pathways that regulates vasculogenesis and angiogenesis is 
the vascular endothelial growth factor-A (VEGF) pathway. VEGF-A is a secreted cytokine 
and plays a role in endothelial cell differentiation, proliferation, migration, survival, vessel 
permeability, and sprouting [7, 8]. Genetic loss of only one copy of the VegfA gene leads to 
embryonic lethality at an early stage (between E8.5-E9.5) [9], highlighting the importance of 
this signaling pathway during development. Since the discovery of VEGF and its critical role 
in angiogenesis, other pathways that also regulate sprouting angiogenesis have emerged, such 
as BMP, Wnt, and Notch pathways [10-12].  
Sprouting angiogenesis, the main driving force increasing vessel density, initiates 
when endothelial cells receive extracellular stimuli and guidance cues that alter intracellular 
cytoskeletal dynamics and polarity to initiate outward migration from the parent vessel and 
become tip cells, the leading cells of sprouts [13-15]. The endothelial cells that trail behind 
the tip cells are termed “stalk” cells [11, 14]. Stalk cells are primarily involved in sprout 
elongation and lumen formation. Differences in protein expression between neighboring 
endothelial cells establish the heterogeneity essential for tip/stalk cell selection and activation 
of downstream signaling components [16, 17]. Molecular signatures for both tip and stalk 
cells have been identified, most notably in the Notch and VEGF pathways [11, 18]. Tip cells 
have increased VEGF Receptor 2 (VEGFR-2) and Delta-like 4 (Dll4) signaling, while stalk 
cells have increased Notch and VEGF Receptor 1 (VEGFR-1) signaling [11]. However, the 
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crosstalk between these and other pathways have led to a more complex regulatory network 
that includes feedback loops and receptor stability [19-22]. BMP signaling also impacts 
sprouting angiogenesis and will be discussed in a later section. 
 
1.1 Angiogenesis during development, physiological and pathological conditions 
I have examined blood vessel growth during development and in adults. In this section, I 
highlight the similarities and differences between angiogenesis in embryos, adults, and 
during disease.  
 
Developmental angiogenesis 
During embryonic development, sprouting angiogenesis increases the vascular 
network. This expansion perfuses the embryo with blood vessels to provide the essential 
nutrients and oxygen required for proper growth. Because blood vessels are a critical 
component for development, perturbations in the pathways that regulate angiogenesis lead to 
embryonic lethality. For example, global deletion of any of the VEGF receptors (Vegfr-1,2,3) 
which bind VEGF ligands leads to embryonic lethality between E8.5-E12.5 [23]. The 
phenotypes associated with deletion of each receptor can vary as they each have different 
roles in the pathway. Vegfr1-/- embryos have excessive endothelial proliferation and lumen 
obstruction [24, 25], Vegfr2-/- embryos have deficient endothelial cell differentiation and lack 
blood vessels [26], and Vegfr3-/- embryos have vascular remodeling defects and pericardial 
fluid accumulation [27]. To add another level of complexity, the VEGF receptors can also 
form heterodimers with each other, as well as other co-receptors, such as neuropilins [23]. 
Although I have only described the VEGF-A pathway in short, there are many more 
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signaling pathways that contribute to developmental angiogenesis [5, 6, 12, 14]. 
Additionally, crosstalk between multiple pathways is critical for proper vessel patterning of 
the embryo.    
 
Physiological angiogenesis 
During physiological angiogenesis, some of the similar pathways that drive 
developmental angiogenesis are still present, such as VEGF-A. However, a significant 
difference between developmental and physiological angiogenesis is the infiltration of 
inflammatory cells, such as neutrophils and macrophages, that secrete growth factors to 
recruit and generate new blood vessels during physiological angiogenesis [28]. 
Most vascular endothelial cells in adults are non-mitogenic and quiescent [5]. Yet, 
endothelial cells are activated in adults during physiological and pathological angiogenesis. 
Physiological angiogenesis refers to natural processes in which blood vessels are required to 
aid in tissue turnover, such as wound healing or menstruation, or provide enhanced 
enrichment, such as pregnancy [28]. During physiological angiogenesis, growth factors, such 
as VEGF-A, placental growth factor (PGF), and fibroblast growth factor (FGF), become 
secreted to activate endothelial cells to migrate, sprout, and form new vessels in a process 
termed neovascularization [28, 29]. However, after the new tissue is healed or pregnancy is 
complete, the newly formed blood vessels are no longer necessary and apoptosis of 
endothelial cells occurs to prune the vascular network as well as cessation of growth factor 
secretion to prevent new vessels from forming [30, 31]. In this manner, physiological 






Pathological angiogenesis is the growth of new blood vessels associated with disease. 
Pathological angiogenesis shares many characteristics with developmental and physiological 
angiogenesis, such as inflammation and increased growth factor and cytokine signaling [28]. 
However, during pathological angiogenesis, pro-angiogenic signaling mechanisms persist, 
leading to disordered endothelial cells and/or an increased vascular network [28]. 
Pathological angiogenesis can aid diseases in many ways. For instance, tumor cells secrete 
growth factors and cytokines to activate pro-angiogenic pathways and recruit vessels. Blood 
vessels then aid tumors by 1) increasing nutrient and oxygen delivery to the tumor, allowing 
the tumor to grow rapidly and 2) providing more avenues for tumor cells to intravasate into 
the vessels and metastasize at new sites [32, 33]. Since pathological angiogenesis activates 
similar pathways to physiological angiogenesis, it is difficult to tease apart therapeutic 
interventions that will only affect pathogenesis without interfering with normal, healing, 
biological processes. 
 
1.2 Wound Healing  
I examine physiological angiogenesis in a wound healing model. Here, I describe the 
properties of wound healing and what is known about angiogenesis during wound healing.  
 
Wound healing demographics and mechanism 
Over thirty-five million cutaneous wounds that require medical intervention occur 
annually in US [34]. Of those, an estimated two to five million result in chronic wounds, or 
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wounds that persist. Patients with diabetes are a higher risk for developing chronic wounds, 
mainly manifesting as foot ulcers that can lead to amputation [35, 36]. The financial costs 
associated with treatment of chronic wounds is high, estimated at $45,000 per patient for 
diabetic foot ulcers alone [37].  Thus, better treatments or faster healing rates of wounds is 
essential for better quality of life and decreased financial burden.   
Wound healing occurs in three main phases: inflammatory, proliferative, and 
remodeling [30, 38, 39]. The inflammatory phase is initiated immediately after a wound is 
made. During this phase, fibroblasts and polymorphonuclear cells invade the wound site and 
secrete growth factors promoting vessel growth and remodeling [30, 40]. Fibroblasts also 
deposit extracellular matrix (ECM) to support subsequent cellular influx and angiogenic 
growth [38].  In the proliferative phase, angiogenesis occurs in response to secreted growth 
factors from macrophages and keratinocytes to facilitate nutrient delivery to the wound site 
[37]. Proliferation of endothelial cells at this stage is critical, as vessels are the main conduits 
for transport of immune cells and nutrients to the wound, and wounds are not able to heal 
properly without sufficient vasculature [41]. In the remodeling phase, the wound has finished 
healing and the programs that became active in the previous phases are turned off. During 
this phase, the wound contracts, angiogenesis ceases, apoptosis of various cell types, 
(including endothelial cells) occurs, and a scar is formed where the tissue was once broken 
[30].  
 
Angiogenesis during wound healing 
Neovascularization is robustly activated during wound healing and new vessels are 
mainly formed through angiogenesis. The inflammatory response initiated by tissue injury 
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stimulates macrophages and keratinocytes to produce high levels of VEGF [42]. Moreover, 
VEGF is produced in response to hypoxia at the wound site [43].  In addition to VEGF, 
fibroblast growth factor -2 (FGF-2), platelet-derived growth factor (PDGF), TGF-β ligands, 
BMP ligands and more are secreted to promote angiogenesis [44]. The influx of pro-
angiogenic factors stimulates capillaries to grow rapidly, filling the wound with a vascular 
network that can be up to ten times more dense than normal tissue [43]. Notably, most of the 
newly formed vessels are immature, leaky, and nonfunctional [45]. After the proliferative 
phase, the vascular network is pruned back to normal levels. Failure of vascular pruning can 
lead to increased scarring and decreased strength in the newly generated tissue [45].   
In chronic, nonhealing wounds, inflammation persists and there is a delay or no 
progression to the remodeling phase [45]. Chronic wounds show a decrease in angiogenesis 
and overall less vessels in the regenerated tissue. Studies in which ischemia is induced in 
Type 2 diabetic mice show that diabetic wounds have delayed wound healing rates due to 
persistent inflammation [46] and decreased angiogenesis [47]. Decreased vascular networks 
in wounded tissue can lead to necrosis and limb amputation in extreme cases [48, 49]. On the 
other hand, increasing angiogenesis at the wound site accelerates the rate of wound healing 
[50, 51]. For this reason, current wound healing therapies are focused on increasing vessel 
density near the wound. One example consists of building vascularized scaffolds that can 
biodegrade once transplanted into wounded tissue [41] or scaffolds that are embedded with 
growth factors to attract more blood vessels [52]. Yet, other studies are focused on the 
potential of stem cells to jumpstart endothelial differentiation and increase vessel formation 
at the wound [46, 53]. Since increasing angiogenesis at the would correlates to accelerated 
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wound healing [50], understanding mechanisms that increase vessel density at the wound site 
are of great interest. 
 
1.3 Tortuous Vessels 
My thesis project uncovered a previously unknown characteristic of tortuous vessels, 
sprouting, that I observed during wound healing. Here, I describe what is known about 
tortuous vessels and what diseases are associated with formation of tortuous vessels.  
 
Tortuous vessel morphologies and characteristics 
Tortuous vessels are abnormal vessels characterized as having oscillating S curves, 
kinking/bending, looping, or a spiral twisting morphology (Figure 1.1) [54]. Although these 
vessels have been observed for decades in many diseases and in wounds, the mechanisms 
correlated to the causes and consequences of tortuous vessels remain poorly understood. Part 
of the difficulty in studying tortuous vessels is that these vessel types have only been 
observed in vivo, making it challenging to unravel the complex signaling mechanisms using 
genetic tools. Clinical observations have linked tortuous vessels with wounds, aging, 
atherosclerosis, hypertension, genetic defects and diabetes, and are many times used as a 
prognostic biomarker for these diseases [54].  Tortuous vessels have decreased or abnormal 
endothelial cell junctions [55] and as a consequence, are leaky and permeable [56]. Of note, 
innate tortuous vessels exist, such as collateral vessels, that do not share characteristics with 
disease-associated tortuosity aside from their distinct morphologies [57]. Thus, the 
information provided in this section focuses on tortuous vessels that arise from pathogenesis 




Causes of tortuous vessel formation 
Although the mechanisms involved in tortuous vessel formation have not been 
elucidated, some implicated factors include: 1) biomechanical forces, such as an increase in 
blood pressure [58], 2) reduced axial tension due to vessel elongation [59], 3) weakening of 
the arterial wall or surrounding extracellular matrix [60, 61], and 4) an influx of growth 
factor and cytokine secretion [62-64]. Additional studies have hypothesized mechanical 
instability and remodeling as one of the mechanisms for initiation and development of 
tortuous vessels [54, 65, 66].  
Changes in mechanical forces, induced by blood flow, leads to altered endothelial cell 
gene expression. Computational models predict that curved vessels experience increased 
shear stress on the outer curvature [67] and that S-curved vessels experience disturbed flow 
that is positively correlated to vessel diameter [68]. Genes associated with inflammation, 
such as vascular cell adhesion molecule 1 (VCAM-1), are upregulated by endothelial cells 
experiencing disturbed flow [69]. Furthermore, studies using microarrays performed in 
human aortic endothelial cells (HAEC) reveal a subset of genes that are differentially 
expressed under laminar and disturbed flow conditions [70]. This differential activation of 
downstream signaling components leads to endothelial cell heterogeneity between cells in 
normal and tortuous vessels.  
One of the signaling events that is compromised is the crosstalk between tortuous 
endothelial cells and smooth muscle cells. Disturbed flow activates signals that instruct 
smooth muscle cells to relax [71] which in turn activates proliferation of endothelial cells 
within tortuous vessels [72, 73]. The increase in proliferation is confined to a vessel segment 
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that is connected to other vessels at both endpoints. Because the vessel segment is not able to 
extend and is experiencing increased rates of cell division, it will buckle and take on the 
hallmark appearance of tortuosity [54]. Additionally, alterations in the ECM can induce 
tortuous vessel formation. Pietramaggiori et al. showed that applying a continuous tensile 
strength of 0.50 Newtons to the rat ear, induced matrix changes and caused vessels to 
become tortuous [74]. Genetically, tortuous vessel formation has been linked to 
overexpression of the growth factors VEGF-A [75, 76] and VEGF-C [63], loss of the 
transcription factor Elk3 [77], and deletion of the ECM component Fibulin5 [61].  
 
Tortuous vessels during wound healing 
Tortuous vessels have been observed during wound healing by use of dye injection 
[66] and Doppler imaging or laser speckling which uses blood flow to visualize blood vessels 
[78, 79]. During wound healing, the number of tortuous vessels increases during the 
inflammatory and proliferative phases, and then decreases as the wound enters the 
remodeling phase [79]. However, the mechanisms that lead to tortuous vessel resolution 
during the remodeling phase have not been addressed.  
The wound healing response mimics the early stages of tumorigenesis in many ways, 
including the formation of tortuous vessels. The microenvironments of tumors and wounds 
share many similarities, including inflammation, hypoxia, and increased growth 
factor/cytokine signaling, and for this reason tumors have been described as “wounds that do 
not heal” [80]. However, a significant difference is that tortuous vessels in a wound 
environment resolve after the wound is healed, whereas cancer tortuous vessels maintain 
their tortuosity, possibly due to the constant secretion of growth factors by the tumor [81]. 
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Current therapies to improve drug delivery to tumors are aimed at normalizing tortuous 
vessels surrounding tumors [82, 83]. Therefore, by understanding the process of tortuous 
vessel formation in an environment that is similar to cancer, but is able to repair itself, we 
can begin to unravel therapeutic targets towards tumor angiogenesis. Surprisingly, tortuous 
vessels have not been noted during development, even though growth factor signaling and 
hypoxic environments are present [84]. However, one component that is low during 
development, is the inflammatory response [43] which suggests that inflammation plays an 
important role in tortuous vessel formation.  
 
1.4 BMP signaling in angiogenesis during development and disease 
I have found that deletion of one of the BMP receptors, BMPR2, disrupts developmental 
angiogenesis. This section provides background on BMP signaling and what is known about 
BMPs and angiogenesis. 
 
BMP signaling pathway 
Bone morphogenetic proteins (BMP) are members of the transforming growth factor 
(TGF)-β superfamily, which includes TGF-β and activins. BMP ligands form hetero- or 
homodimers that bind to BMP receptors with varying affinity [85]. Ligands bind to 
heterotetrameric receptors made up of two type I and two type II BMP receptors. The type II 
receptor, BMPRII, is constitutively active and present as two variants, a short form and a 
long form that contains a long cytoplasmic tail [85]. Once in a complex, BMPRII 
phosphorylates type I receptors, initiating downstream canonical signaling through Smad 
transcription factors or non-canonically through MAPK/ERK [86]. Smad signaling is 
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initiated by phosphorylation of R-SMADs (SMAD 1/5/8) which then recruit SMAD4. This 
complex translocates to the nucleus and promotes transcription of downstream target genes, 
such as inhibitor of DNA binding 1 (Id1) [87]. Inhibitors regulate the BMP pathway at the 
extra- and intracellular level. Secreted antagonists, such as NOGGIN and CHORDIN, bind to 
BMP ligands and block their receptor binding sites [88]. Decoy receptors, such as BAMBI, 
compete with Type I receptors for complex formation with BMPRII and ligand binding [89]. 
SMAD6, an inhibitory Smad (I-Smad), can inhibit Smad signaling by binding to the R-Smad 
site on the Type I receptor, forming a non-functional complex with SMAD4, or interacting 
with transcriptional co-repressors in the nucleus [85]. At least twenty BMP ligands have been 
identified in mammals [10, 90]. Due to the large number of ligands and the dynamic 
interplay between ligand and receptor signaling, there are still many aspects of BMP 
signaling that continue to be revealed. Future work in illuminating BMP-signaling dynamics 
and disease relevance will be required to better understand this complex signaling pathway. 
 
BMP signaling in angiogenesis 
BMP ligands and receptors are expressed in endothelial cells during development and 
in adults [10, 91]. Recent studies have shown that some BMP ligands and receptors act as 
pro-angiogenic cues to induce sprouting angiogenesis [92-94]. For example, Bmp2b over-
expression in zebrafish embryos causes ectopic vessel formation [95]. Interestingly, ectopic 
vessel formation is only induced from veins and occurs independently of VEGF signaling, 
indicating that BMP initiates sprouting in distinct vascular beds. Further studies in a human 
umbilical vein endothelial cell (HUVEC) based sprouting angiogenesis model show that 
BMP ligands promote lateral branching, implying that certain cells within a vessel are more 
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responsive to BMP and will sprout in a high BMP environment [96]. In another sprouting 
HUVEC spheroid model, BMP4 ligand induces vessel sprouting via ERK signaling [90]. 
Additional studies show that the type I BMP receptor, ALK3, is recruited to the tips of 
filopodia, thin actin based cell extensions that project from tip cells [97]. Dynamic filopodial 
extensions that sense and respond to the microenvironment are associated with tip cells and 
their forward migration. Pi et al. found that BMP6/ALK3 mediated signaling increased 
filopodial extensions, driving endothelial cell migration. However, the BMP9/BMP10/ALK1 
signaling axis has been shown to have an anti-angiogenic role. Using blocking antibodies 
against BMP9, BMP10, or ALK1 injected into the postnatal retina, Ricard et al. found 
disrupted vasculature, mainly an increase in vascular density [98]. Overall, these results 
highlight the complexity of the BMP signaling pathway. Further studies are required to 
understand the mechanisms of BMP-guided sprouting angiogenesis and to examine the 
effects of BMP signaling in different vascular beds. 
 
BMP signaling during disease and wound healing 
In addition to angiogenesis, BMP signaling is also involved in maintaining 
endothelial cell integrity in adult cells [91]. Haploinsufficiency for BMPR2 leads to 
pulmonary arterial hypertension (PAH) in mice [99], a disease in which lung capillaries 
become occluded, leading to increased blood pressure as the heart pumps harder to 
compensate for the increased resistance. Additionally, loss of BMPR2 is associated with 
increased inflammation.  Studies performed by Kim et al. showed that deletion of BMPR2 in 
HUVEC and human aortic endothelial cells (HAEC) lead to increased levels of inflammatory 
markers such as vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion 
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molecule 1 (ICAM-1) [100]. The authors used a heterozygous BMPR2 mutant mouse line to 
show that ICAM-1 and VCAM-1 were also upregulated in endothelial cells within the mouse 
thoracic aorta in this genetic background. Overall, these studies point to an important role for 
BMP signaling, and in particular BMPR2, in maintaining adult homeostasis. 
During wound healing, BMP signaling activity becomes up-regulated in epithelial 
cells [101]. BMP2,4,6, and 7 are all expressed in wound tissue [102]. In particular, 
expression of BMP6 increases in keratinocytes and fibroblasts 2-3 days after an injury and 
regulates macrophage proliferation and dendrite cell maturation at the wound [103]. Studies 
in which downstream signaling components of the canonical BMP pathway were altered 
resulted in aberrant wound healing. Overexpression of Smad1 from keratinocytes resulted in 
increased apoptosis and decreased migration of wound epithelium as well as an inability to 
reorganize the cytoskeleton in epithelium, resulting in delayed wound healing [104]. 
Surprisingly, conditional deletion of Smad4 from the epidermis, also resulted in delayed 
wound healing [105]. However, in this case the delay is due to excessive inflammation and 
angiogenesis through upregulation of TGFβ1. Although BMP signaling has been studied 
during wound healing to some degree, the effects of BMPs on endothelial cells during wound 
healing remains relatively understudied. 
 
1.5 Summary 
Angiogenesis plays an important role during development, wound healing, and 
disease. Although, the signaling pathways contributing to angiogenesis are conserved, the 
outcomes of activating angiogenesis during development or disease can vary. Here, I show 
that endothelial specific deletion of Bmpr2 in the postnatal retina leads to decreased 
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sprouting at the vascular front as well as branching in vascular plexus. These studies suggest 
that BMPR2 contributes to vascular patterning of the retina and is required for retinal 
sprouting angiogenesis. 
A consequence of pro-angiogenic signaling during wound healing and disease is the 
formation of tortuous vessels. Tortuous vessels can be used as a therapeutic target to combat 
many diseases, ranging from cancer to diabetic ischemia. Thus, it is imperative to understand 
the mechanisms leading to tortuous vessel formation and resolution. Here, I provide a 
detailed investigation of tortuous microvessel (5-20 µm in diameter) formation and resolution 
at the cellular level during wound healing and analyze a new characteristic of tortuous 
microvessels, tortuous vessel sprouting. 
 





Figure 1.1 Morphology of normal and tortuous vessels.  
Normal vessels are linear or have a slight curve. Tortuous vessels have a sinusoidal S shape 
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Chapter 2:  Alk2/ACVR1 and Alk3/BMPR1A Provide Essential Function for Bone 
Morphogenetic Protein Induced Retinal Angiogenesis1 
 
2.1 Summary 
Increasing evidence suggests that Bone Morphogenetic Protein (BMP) signaling 
regulates angiogenesis. Here, we aimed to define the function of BMP receptors in regulating 
early post-natal angiogenesis by analysis of inducible, endothelial specific deletion of the 
BMP receptor components Bmpr2, Alk1, Alk2 and Alk3 in mouse retinal vessels. Expression 
analysis of several BMP ligands showed that pro-angiogenic BMP ligands are highly 
expressed in postnatal retinas. Consistently, BMP receptors are also strongly expressed in 
retina with a distinct pattern. To assess the function of BMP signaling in retinal angiogenesis, 
we first generated mice carrying an endothelial-specific inducible deletion of BMP Type 2 
receptor (Bmpr2). Postnatal deletion of Bmpr2 in endothelial cells substantially decreased the 
number of angiogenic sprouts at the vascular front and branchpoints behind the front, leading 
to attenuated radial expansion. To identify critical BMPR1s associated with BMPR2 in 
retinal angiogenesis, we generated endothelial-specific inducible deletion of three BMPR1s 
abundantly expressed in endothelial cells and analyzed the respective phenotypes. Among 
these, endothelial specific deletion of either Alk2/acvr1 or Alk3/Bmpr1a caused a delay in 
                                               
1 This chapter previously appeared as an article in Arteriosclerosis, Thrombosis, and Vascular Biology. The 
original citation is as follows: Heon-Woo Lee*, Diana C. Chong*, Roxana Ola*, William P. Dunworth, Stryder 
Meadows, Jun Ka, Vesa M. Kaartinen, Yibing Qyang, Ondine Cleaver, Victoria L. Bautch, Anne Eichmann, 
Suk-Won Jin. Alk2/ACVR1 and Alk3/BMPR1A Provide Essential Function for Bone Morphogenetic Protein–
Induced Retinal Angiogenesis. ATVB. 2017 Apr;37(4):657-663. http://atvb.ahajournals.org  
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radial expansion, reminiscent of vascular defects associated with postnatal endothelial 
specific deletion of BMPR2, suggesting that ALK2/ACVR1 and ALK3/BMPR1A are likely 
to be the critical BMPR1s necessary for pro-angiogenic BMP signaling in retinal vessels. Our 
data identify BMP signaling mediated by coordination of ALK2/ACVR1, ALK3/BMPR1A, 




Bone Morphogenetic Protein (BMP) signaling has been implicated as a key regulator 
for angiogenesis [1]. Depending on the nature of the ligands, BMP signaling can either 
promote or inhibit angiogenesis [2]; Pro-angiogenic BMP2/4 augments vessel sprouting in a 
matrigel plug assay [3], and stimulation with BMP2 promotes angiogenic responses such as 
filopodia extension and migration in human umbilical vein endothelial cells (HUVEC) by 
inducing the expression of target genes, such as MYOX [4]. In addition, its zebrafish 
orthologue, Bmp2b, functions as the predominant angiogenic cue for veins [5, 6]. Similar 
pro-angiogenic effects have been demonstrated for BMP6 [4, 7]. In contrast, BMP9 and 
BMP10 induce quiescence of endothelial cells, and therefore function as anti-angiogenic cues 
[8-10]. Consistent with the idea that BMP9 and BMP10 modulate the homeostasis of mature 
vessels, it has been shown that BMP9 can promote differentiation of endothelial progenitors 
during ischemic neovascularization [11]. 
On the cell membrane of the signal receiving cells, BMP ligands interact with tetra-
heteromeric receptor complexes composed of two BMP Type 1 Receptors (BMPR1s) and 
two BMP Type 2 Receptors (BMPR2s). The signaling specificity of each BMP ligand is 
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determined by the interaction between BMP ligand and its cognate BMPR1, since BMPR2 
can only serve as a low affinity receptor [12, 13]. Therefore, BMPR1s are essential for the 
outcomes of BMP signaling. In the mammalian genome, four BMPR1s, Alk1/Acvrl1, 
Alk2/Acvr1, Alk3/Bmpr1a, and Alk6/Bmpr1b, have been annotated [14, 15]. Previous work 
showed that endothelial-specific deletion of Alk1 generates exuberant angiogenesis, 
indicating that ALK1 is likely to mediate anti-angiogenic BMP9/10 signaling in endothelial 
cells [9, 16, 17]. Considering that ALK2, ALK3, and ALK6 bind to BMP2, BMP4, and 
BMP6 in other circumstances [18], these receptors are likely to mediate pro-angiogenic BMP 
signaling. However, since global deletion of these receptors leads to early embryonic 
lethality [19-22], surprisingly little is known about the individual function of these BMPR1s 
in endothelial cells. In addition, previous attempts to elucidate the role of each BMPR1 in 
endothelial cells failed to provide comprehensive analyses due to the lack of suitable 
endothelial-specific Cre driver lines [23, 24]. Most importantly, manipulations of BMPR1 in 
endothelial cells were not performed in the same way in the same vascular bed in previous 
studies, making it difficult to determine the role of each BMPR1s in endothelial cells [23, 
24]. 
In this study, we investigated the function of each BMPRI in angiogenesis using 
postnatal mouse retinal vessels to better understand the molecular and cellular underpinning 
of pro-angiogenic BMP signaling. To assess the contribution of BMPs in retinal 
angiogenesis, we showed BMP signaling reporter activity in the early postnatal retina, and 
found that BMP6 and BMP7 are the most abundant BMP ligands in that organ. We found 
that several BMPR1s were expressed in distinct regions of the retinal vasculature. 
Conditional deletion of Bmpr2 and three highly expressed BMPRIs, Alk1/Acvrl1, Alk2/Acvr1, 
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and Alk3/Bmpr1a, in endothelial cells of postnatal mice showed that mice deficient for 
Alk2/Acvr1 or Alk3/Bmpr1a partially phenocopied the vascular defects of mice with an 
endothelial specific deletion of Bmpr2. Taken together, our data indicate that the pro-
angiogenic BMP signaling mediated by ALK2 and ALK3 receptors, likely in conjunction 
with BMPR2, is essential for proper retinal angiogenesis. 
 
2.3 Materials and Methods 
 
Genetic experiments and pharmacological inhibition 
All animal procedures were performed in accordance with Yale University and 
University of North Carolina Institutional Animal Care and User Committee guidelines. The 
following mouse strains were used: Alk1fl/fl [25], Alk2fl/fl [26], Alk3fl/fl [27], Bmpr2fl/fl [28], and 
Cdh5(Pac)CreERT2 [29], and BRE-gfp [30] mice. For endothelial-cell-specific loss-of-
function of BMPRs, mice carrying homozygous floxed alleles of BMPR were interbred with 
Cdh5(Pac)CreERT2 mice. All of the mouse strains were back-crossed into the C57Bl/6J 
background. Genetic modifications were induced by intraperitoneal injections with 30 or 
100μg tamoxifen (Sigma) at P1 and P2. 
 
Isolation of mouse endothelial cell and manipulation of mouse retina 
Mouse lung endothelial cells (MLECs) for qRT-PCR analyses were isolated as 
described previously [31, 32]. In total, six P6 pups were euthanized by decapitation. The 
lungs were removed and placed in a 1.5mL eppendorf tube. Lungs were finely minced with 
sharp scissors, then the tissue was digested with 2mg/mL collagenase type I in PBS at 37°C 
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for 45 min. The digest was passed through a 75μm cell strainer to remove undigested tissue 
fragments. Cells were pelleted at 400 g for 5 minutes, resuspended in 2% FBS containing 
PBS with magnetic beads-coated rat anti-mouse CD31 (PECAM-1) antibody (Ab) (BD 
PharMingen). After incubation on room temperature for 12 min, the cells were placed on the 
magnet for 5 min and unbound cells were removed. The bound cells were resuspended in 
medium and plated onto a 0.1% gelatin-coated dish. Mouse retina dissection and 
manipulation was performed as previously reported [33]. 
 
Immunofluorescence (IF) 
The following antibodies were used: anti-ALK1 (1:100, R&D Systems), anti-ALK2 
(1:100, Proteintech), anti-ALK3 (1:100, Thermo), anti-BMPR2 (1:100, BD), anti-PECAM-1 
(1:200, BD) and isolectin-B4 (1:100, BD). Alexa Fluor 488, 555 and 647 donkey secondary 
antibodies were from Invitrogen. Retina immunostaining was carried out with littermates 
processed simultaneously under the same conditions. To analyze and quantify the retina 
vascular phenotype, the eyes were fixed in 4% PFA for 2 hours at 4°C and dissected as 
previously reported (REF). After washing the retinas were permeabilized using PBS-T (0.1% 
Triton X-100 containing PBS) and incubated overnight at 4°C in PBS-T containing 
biotinylated isolectin B4 (IB4) and the primary antibodies. Then the retinas were incubated 
with fluorophore-conjugated antibodies and with Alexa Fluor 488/555/647 (Invitrogen), and 
mounted with Fluorescence Mounting Medium (Dako). Confocal microscopy was performed 
with Leica SP5 confocal microscopes. ImageJ (NIH) was used for the data analysis. The 
figures were assembled using Adobe Photoshop. The only adjustments used in the 
preparation of the figures were for brightness and contrast. RT-PCR For gene expression 
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analysis, the total RNA was isolated with RNeasy Mini kits (QIAGEN) and 1 μg total RNA 
was reverse transcribed using High-Capacity cDNA Reverse Transcription Kit (Thermofisher 
scientific) following the manufacturer instructions. The cDNAs were amplified using the FG 
Power SYBR Green PCR Master Mix (Applied Biosystems) in an Eppendorf Mastercycler 
gradient. The relative expression differences represent the means of the results obtained from 
at least three-independent experiments. 
 
Statistical analysis 
Data are expressed as mean ± SEM. Comparisons between groups were made using a 
two-tailed Student t test. Prior to the student t test, we have used the Levene's test to examine 
whether the assumptions and conditions for t test were violated, and therefore, could not be 
used to determine the differences between groups. We found that knockout mice and 
phenotypic wild-type siblings are statistically indistinguishable groups for a number of 
unrelated parameters. In all parameters we used, the F values were significantly smaller than 
the Table F value at α=0.001. Our statistical analyses demonstrated that knockout mice and 
their phenotypic wild-type siblings have similar population variances, and therefore, the 
assumptions and conditions for t test was not violated. This result supports our approach to 
employ t test to perform statistical analyses. 
 
2.4 Results 
Diverse BMP ligands and receptors are expressed during retinal angiogenesis 
To determine the role of pro-angiogenic BMP signaling, we first examined the 
expression of GFP in retinal vessels of BRE-GFP mice, where the expression of GFP is 
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regulated by BMP Responsive Elements (BRE) isolated from the Id1 promoter [34]. As 
previously reported [30], BRE-GFP expression was broadly detected in P5 retinal vessels 
(Figure 2.1A). Within the vascular front, BRE-GFP was highly expressed in both tip and 
stalk cells (Figure 2.1B). While the expression of BRE-GFP in stalk cells can be attributed to 
the ALK1-mediated anti-angiogenic BMP signaling activity [9, 30], it is not clear how BRE-
GFP expression in tip cells is induced. 
To identify which BMP ligands and receptors induce BRE-GFP expression in the 
retinal vessels, we performed in situ hybridization analyses on mouse retinas and quantitative 
RT-PCR using cells isolated from postnatal retinas at different developmental stages (Figure 
2.1C and Supplementary Figure 2.1). A number of pro-angiogenic BMP ligands were 
highly expressed during the stages coincident with extensive retinal angiogenesis (Figure 
2.1C and Supplementary Figure 2.2). In particular, the expression of BMP6 and BMP7, 
was increased over two folds. In contrast, expression of BMP9 and 10, which are ligands for 
ALK1 and are produced by liver and heart respectively, were not detected in the retina 
(Supplementary Figure 2.1). However, given that they are delivered by circulation, it is 
likely that the mature BMP9 and BMP10 protein are present in the retina. In endothelial 
cells, only three BMPR1s, ALK1, ALK2, and ALK3, but not ALK6, were highly expressed. 
Therefore, ALK6 was excluded from further analyses (Supplementary Figure 2.3). 
Next, we analyzed the expression of BMPR2 and the three BMPR1s that are abundant 
in endothelial cells, ALK1/ACVRL, ALK2/ACVR1A, and ALK3/BMPR1A by 
immunostaining in retinas (Figure 2.1D-G and data not shown). BMPR2 staining is vascular 
and appears in all vessels, with heightened expression at the vascular front (Figures 2.1D 
and H). Interestingly, each BMPR1 has distinct expression pattern; ALK1 and ALK3 
33 
 
proteins are found in both plexus and vascular front, with ALK1 being enriched in the 
arteries of the plexus region. ALK2 staining is highly enriched in veins in the plexus region 
and not associated with the vascular front or arteries (Figures 2.1E-G and I-K). These 
findings show that pro-angiogenic BMP ligands and receptors are highly expressed in blood 
vessels during retinal development, and the receptors have distinct expression patterns. 
Therefore, it is likely that BRE-GFP reporter activity in tip cells at the vascular front results 
from the activity of proangiogenic BMP ligands. 
 
BMPR2 activity promotes retinal angiogenesis 
To examine the requirement for pro-angiogenic BMP signaling during retinal 
angiogenesis, we generated mice carrying an inducible, endothelial-specific Bmpr2 deletion 
by crossing Bmpr2fl/fl and Cdh5(Pac)CreERT2 mice27. Given that BMPR2 is the predominant 
binding partner for BMPR1s mediating pro-angiogenic BMP activity, we postulated that 
deletion of Bmpr2 is likely to attenuate signaling outcomes downstream of most pro-
angiogenic BMP ligand engagement during retinal angiogenesis. Consistent with our 
hypothesis, endothelial cell deletion of Bmpr2 significantly decreased the radial expansion of 
the retinal vessels (Figures 2.2A and C), indicating that BMP signaling is essential for retinal 
angiogenesis.  Bmpr2fl/fl;Cdh5(Pac)CreERT2 mice also displayed a significant reduction in 
vascular density (% vascularized area) compared to wild-type littermates (Figures 2.2B and 
C). This data shows that pro-angiogenic BMP signaling mediated by BMPR2 is a critical 





Endothelial specific deletion of Alk2/ACVR1A or Alk3/BMPR1A but not Alk1/ACVRL 
recapitulates vascular defects of endothelial specific deletion of Bmpr2 
Next, we investigated critical BMPR1 interactions mediating pro-angiogenic BMP 
signaling during retinal angiogenesis. Endothelial deletion of Alk1, Alk2, or Alk3 during 
postnatal retinal angiogenesis was induced by crossing homozygous mice carrying a floxed 
allele of each BMPR1 and Cdh5(Pac)CreERT2 mice (Supplementary Figure 2.4). As 
previously reported [9, 29], tamoxifen-mediated deletion7 of Alk1 in endothelial cells at P1 
did not exhibit severe defects in radial extension, but caused exuberant angiogenesis in 
developing retinas compared to phenotypic wild-type littermates and therefore substantially 
increased vascular density (% vascularized area) (Figure 2.3A, D). In 
Alk1fl/fl;Cdh5(Pac)CreERT2 mice, the vascular phenotype was more pronounced in the 
vascular front than in the plexus region (Figure 2.3A). Considering the distinct phenotypes 
between Bmpr2fl/fl;Cdh5(Pac)CreERT2 and Alk1fl/fl;Cdh5(Pac)CreERT2 mice, it is unlikely that 
ALK1 is involved in pro-angiogenic BMP signaling mediated by BMPR2. 
In contrast, tamoxifen-mediated deletion of Alk2 or Alk3 in endothelial cells at P1 led 
to a substantial reduction in the radial expansion of retinal vessels (Figures 2.3B-C and 
Supplementary Figure 2.4), reminiscent of the defects in Bmpr2fl/fl;Cdh5(Pac)CreERT2 mice 
(Figure 2A). In addition, vascular density was substantially reduced in tamoxifen-injected 
Alk2fl/fl;Cdh5(Pac)CreERT2 or Alk3fl/fl;Cdh5(Pac)CreERT2 retinas compared to wild-type 
littermates (Figure 2.3D). These findings show that both ALK2 and ALK3 are important for 





Endothelial specific deletion of Alk3/BMPR1A and Bmpr2 but not Alk2/ACVR1A affect 
angiogenic sprouts at the vascular front 
Considering that both Alk2 and Alk3 deletion in endothelial cells significantly delayed 
radial expansion but only Alk3 is expressed at the vascular front, we hypothesized that ALK2 
and ALK3 receptors would differentially affect angiogenic sprouts. To examine this notion, 
we first examined the phenotype of endothelial deletion of Bmpr2 and found that lack of 
Bmpr2 significantly decreased the number of angiogenic sprouts (Figure 2.4A). Endothelial 
deletion of Alk3/BMPR1A similarly decreased the number of angiogenic sprouts present at 
the vascular front compared to phenotypic wild-type littermates (Figures 2.4B to C), while 
deletion of Alk2 did not significantly alter the number of angiogenic sprouts at the vascular 
front. Considering that the vascular coverage (% vascularized area) was significantly 
decreased in retinas of mice with deletion of either receptor (Figure 2.3B-D), it is likely that 
different BMPR1 receptors mediate pro-angiogenic BMP signaling at the vascular front and 
behind the front. 
 
2.5 Discussion 
Our results identify BMPR2/ALK2 and BMPR2/ALK3 as key receptors that mediate 
pro-angiogenic BMP signaling in the early post-natal retina, and reveal regional differences 
among BMPR1s by analysis of parallel genetic experiments in a defined vascular bed. 
Deletion of the common BMPR2 receptor reduced vascular sprouting and density. Deletion 
of ALK3, which is ubiquitously expressed in retinal endothelial cells, also dramatically 
reduced vascular sprouting and density, while loss of ALK2, which is enriched behind the 
vascular front, did not significantly affect sprouting but reduced overall vessel density. 
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Therefore, we propose that spatially regulated BMPR1 expression fine-tunes endothelial cell 
responses to pro-angiogenic BMP ligands in development. Since expression of BMP ligands 
selective for ALK2 and ALK3 is elevated during retinal angiogenesis, it is tempting to 
speculate that BMP6/7-ALK2/3-BMPR2 signaling axis may provide essential input for the 
developing retina. 
Since the phenotype of endothelial-specific deletion of Bmpr2 is quite distinct from 
the vascular phenotype caused by endothelial-specific deletion of Alk1, it is likely that 
BMPR2-mediated proangiogenic signaling is dominant over interactions with ALK1 in the 
early postnatal retina. In contrast, ALK2 and ALK3 appear to be essential for BMPR2-
mediated pro-angiogenic signaling. These receptors function similarly but non-redundantly 
behind the vascular front in mediating branching, as deletion of either Type 1 receptor 
partially phenocopies the phenotype of Bmpr2 deletion and results in reduced branching. 
This finding suggests that both ALK2/BMPR2 and ALK3/BMPR2 complexes contribute to 
branching morphogenesis, which is consistent with our previous finding that proangiogenic 
BMP signaling leads to increased branching in vitro and in vivo [5, 6]. Angiogenic sprouting 
at the vascular front is likely to selectively utilize ALK3/BMPR2 complexes, since genetic 
deletion of Alk2 did not significantly affect angiogenic sprouting. This is consistent with the 
expression patterns of the receptors in the early postnatal retina, as ALK3 but not ALK2 
reactivity was found at the vascular front. ALK2 reactivity is enriched in veins, while ALK3 
expression is not enriched in larger vessels, suggesting potential differences in ALK2 and 
ALK3 mediated pro-angiogenic BMP signaling. 
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ALK1, which does not appear to be essential for BMPR2-mediated pro-angiogenic BMP 
signaling, may provide an additional regulation for vessel remodeling and homeostasis at 
later stages. 
Previously, it has been shown that BMPR1s can promiscuously form heterodimeric 
complex [16, 35-37]. For instance, it has been shown that ALK1 and ALK2 can form 
heterodimers under certain circumstances [36, 37]. Similarly, ALK2 and ALK3 are proposed 
to form heterodimers to mediate BMP2 signaling [35]. Therefore, it is possible that they may 
influence the signaling property of each other. While we cannot rule of this possibility due to 
the lack of appropriate reagents, given the distinct expression pattern of BMPR1s, we believe 
that the vascular phenotype caused by endothelial specific deletion of single BMPR1 is likely 
to represent the unique signaling property of each receptor. 
Our analyses indicate that ALK3/BMPR2 mediated BMP signaling regulates 
angiogenic sprouting at the vascular front, while both ALK3/BMPR2 and ALK2/BMPR2 
regulate branching behind the vascular front. This is consistent with our finding that BMP 
signaling, as read out by BRE-EGFP, is active throughout the retinal vasculature, and 
suggests that pro-angiogenic BMP signaling regulates both sprouting and branching. These 
results are consistent with a previous report describing ubiquitous expression of BRE-EGFP 
in retinal vessels [30]. 
Our work presents compelling evidence that pro-angiogenic BMP signaling is 
important for angiogenesis. Here we show that expression of Type 1 receptors, specifically 
ALK2 and ALK3, may explain the different effects of BMP signaling on developing vessels, 
and they each likely complex with BMPR2 to mediate pro-angiogenic effects in blood 
vessels in a non-redundant way. While the molecular underpinning of the phenotypic 
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differences between Alk2fl/fl;Cdh5(Pac)CreERT2 and Alk3fl/fl;Cdh5(Pac)CreERT2 mice 
needs further analyses, careful phenotypic comparisons between these mice will help 
elucidate how angiogenesis is regulated in development and disease, and may provide useful 








Figure 2.1. Diverse BMP ligands and receptors are expressed during retinal 
development 
(A-B) Representative overview of retinal vessels at (A) the retinal center and (B) vascular 
front shown in higher magnification in postnatal day P5 BRE-gfp transgenic mice. 
Endothelial cells are shown in red. BRE-GFP is highly expressed in both tip cells and stalk 
cells. (C) qRT-PCR for Bmp ligands and Vegfa in P0, P2, P4, and P6 retina. Bmp6 and 
Bmp7 are the most abundant BMP ligands between P0 and P6 (n=5). (D-G) 
Immunohitochemistry of P5 retina showing BMPR2 (D), ALK1/ACVRL (E), ALK2/ACVR1 
(F), and ALK3/BMPR1A (G). While BMPR2, ALK1 and ALK3 are expressed ubiquitously, 
ALK2 expression is enriched in the veins within the plexus region; scale bar, 300μm. (H-K) 





Figure 2.2. BMPR2 is essential for retinal angiogenesis 
(A) Representative overview of P5 retinal vessels taken from inducible endothelial specific 
knock out of Bmpr2fl/fl;Cdh5(Pac)CreERT2 (right) and their phenotypic wild-type littermates 
(left); scale bar, 500μm. Mean radial expansion of the retinal vessels in P5 Bmpr2fl/fl retinas 
was decreased to 78.9±9.8% of wildtype littermates. (B) Representative overview of plexus 
region of P5 retina in Bmpr2fl/fl;Cdh5(Pac)CreERT2 (right) and their phenotypic wild-type 
littermates (left). Mean vascular density in the plexus region in Bmpr2fl/fl retinas was 
reduced to 65.7±8.3% of wildtype littermates; scale bar, 500μm. Endothelial cells are 
visualized by anti- Isolectin B4 (IB4) staining. (C) Quantification of radial expansion and 
vascular density (% vascularized area) in Bmpr2fl/+;Cdh5(Pac)CreERT2 (gray) and 
Bmpr2fl/fl;Cdh5(Pac)CreERT2 mice injected with 100μg tamoxifen at P1, retinas were assayed 





Figure 2.3. ALK2 and ALK3 promotes retinal angiogenesis 
(A-C) Representative overview of retinal vessels taken from inducible endothelial specific 
knock out of Alk1fl/fl;Cdh5(Pac)CreERT2 (A), Alk2fl/fl;Cdh5(Pac)CreERT2 (B), or 
Al31fl/fl;Cdh5(Pac)CreERT2 (C) and their phenotypic wild-type littermates. Mice were injected 
with 50μg tamoxifen at P1, retinas were assayed P5; scale bar, 500μm. Both radial expansion 
and vascular density in the plexus region were significantly increased in P5 
Alk1fl/fl;Cdh5(Pac)CreERT2 retinas (101±6.7% for radial expansion and 155±6.2% for vascular 
density compared to wildtype littermates). By contrast, deletion of either Alk2 or Alk3 
significantly decreased both radial expansion (63.2±17.1% for Alk2fl/f;Cdh5(Pac)CreERT2 
retinas and 56.4±14.2% for Alk3fl/fl;Cdh5(Pac)CreERT2 retinas compared to wildtype 
littermates) and vascular density in the plexus region (42.3±15.9% for 
Alk2fl/fl;Cdh5(Pac)CreERT2  retinas, and 61.9±12.8% for Alk3fl/fl;Cdh5(Pac)CreERT2 retinas 
compared to wildtype littermates). Areas within the white rectangle in middle column are 
shown in higher magnification (right column). While radial expansion was similarly affected 
by deletion of either Alk2 or Alk3, vascular density in the plexus region is more severely 
affected by the deletion of Alk2 than Alk3. Endothelial cells are visualized by anti- Isolectin 
B4 (IB4) staining. (D) Quantification of radial expansion and vascular density (% 
vascularized area) in inducible endothelial specific knockout of each BMPR1 (pink) and their 






Figure 2.4. ALK3/BMPR2 signaling is required for the formation of angiogenic sprouts 
in the vascular front  
(A) Representative image of vascular front in postnatal day P5 Bmpr2fl/fl;Cdh5(Pac)CreERT2 
(A), Alk2fl/fl; Cdh5(Pac)CreERT2 (B), or Alk3fl/fl; Cdh5(Pac)CreERT2 Endothelial cells are 
visualized by anti-Isolectin B4 (IB4) staining. (C) and their phenotypic wild-type littermates. 
Green arrows point the angiogenic sprouts in the vascular front (n=5); scale bar, 200μm. (D) 
Quantification of angiogenic sprouts. The number of angiogenic sprouts in the vascular front 
was measured by dividing the number of angiogenic sprouts by the total length of vascular 
front (See Supplemental methods for detail). While the number of angiogenic sprouts in the 
vascular front was mildly decreased by 20% to in P5 Alk2fl/fl retinas (8.8±0.2 compared to 
10.8±1.9 in wildtype littermates), it was decreased by 45% in 14 Bmpr2fl/fl (6.5±1.3 in 
Bmpr2fl/fl retinas compared to 11.8±1.6 in wildtype littermates), and by 53% in Alk3fl/fl retinas 
(5.3±0.4 in Alk3fl/fl retinas compared to 11.2±0.9 in wildtype littermates). P<0.05. Statistical 





Supplementary Figure 2.1. Expression of BMP ligands in retina during development 
Expression of key BMP ligands and VEGF-A in developing mice retinas over time, 





Supplementary Figure 2.2. Expression of BMP ligands in retinal angiogenesis 
Expression of BMP ligands which appear to be highly expressed in the retina during P1 to P6 





Supplementary Figure 2.3. Expression of BMP receptors in endothelial cells 
Expression of BMP receptors in endothelial cells isolated from mice, measured by qRT-PCR 







Supplementary Figure 2.4. Deletion efficacy of Alk2fl/fl and Alk3fl/fl 
Deletion efficacy of Alk2 and Alk3 upon tamoxifen administration was examined by western 
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Chapter 3: Tortuous Microvessels Contribute to Wound Healing via Sprouting 
Angiogenesis2 
 
3.1 Summary  
Wound healing is accompanied by neoangiogenesis, and new vessels are thought to 
originate primarily from the microcirculation; however, how these vessels form and resolve 
during wound healing is poorly understood. Here, we investigated properties of the smallest 
capillaries during wound healing to determine their spatial organization and the kinetics of 
formation and resolution. We utilized intravital imaging and high-resolution microscopy to 
identify a new type of vessel in wounds, called tortuous microvessels. Longitudinal studies 
showed that tortuous microvessels increased in frequency after injury, “normalized” as the 
wound healed, and were closely associated with the wound site. Tortuous microvessels had 
aberrant cell shapes and distinct interactions with circulating microspheres, suggesting 
altered flow dynamics. Moreover, tortuous microvessels disproportionately contributed to 
wound angiogenesis by sprouting exuberantly and significantly more frequently than nearby 
normal capillaries. A new type of transient wound vessel, tortuous microvessels, sprout 
dynamically and disproportionately contribute to wound healing neoangiogenesis, likely as a 
result of altered properties downstream of flow disturbances. These new findings suggest 
entry points for therapeutic intervention. 
 
                                               
2 This chapter is adapted from a paper submitted to Arteriosclerosis, Thrombosis, and Vascular Biology in 
2017. I performed all of the experiments and wrote the first draft of the manuscript. Dr. Victoria Bautch edited 
and added to my original draft. Dr. Zhixian Yu generated the dot plot in Figure 3.2. Dr. Hailey Brighton and Dr. 




Angiogenesis, the formation of new blood vessels via sprouting, is a complex process 
whereby endothelial cells migrate out from pre-existing vessels and form new connections to 
increase the vascular network [1-5]. During development, angiogenesis occurs in response to 
tissue cues such as hypoxia and is critical for proper growth of the embryo [5-7]. In contrast, 
endothelial cells are largely quiescent in adults; however, they become activated to reinitiate 
angiogenesis in physiological processes such as wound healing or in diseases such as cancer 
[8]. Unlike developmental angiogenesis, physiological angiogenesis is often characterized by 
the formation of tortuous vessels [9-12]. Tortuous vessels have a distinct morphology, 
displaying S-shaped curves, oscillations, or kinks compared to normal linear vessels, and 
they are often excessively permeable [13]. Although tortuous vessels have been observed for 
decades, it is not clear how these vessels form, how they contribute to angiogenesis, or how 
they resolve.  
Wound healing is characterized by several phases [14-16], including a proliferative 
phase in which angiogenesis is a major component. Tortuous vessels often appear during the 
proliferative phase, and their occurrence decreases as the wound heals [17]. Tortuous vessels 
are thought to result from increased cytokine and growth factor signaling, changes in flow 
dynamics, changes in extracellular matrix composition, and/or decreased mural cell coverage 
[9, 13]. Tortuous vessels also have increased permeability [18], which may facilitate delivery 
to the wound site. Tortuous vessels associated with wound healing have been examined at the 
macro level via immunohistochemistry and intravital imaging [13, 17, 19, 20], but it is 
unclear whether tortuosity extends to the smallest capillaries that are the source of most 
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wound-healing angiogenesis, and the cellular parameters associated with formation and 
resolution of vessel tortuosity are poorly understood. 
Here, we use intravital imaging to analyze the role of tortuous capillary vessels, 
called tortuous microvessels, during wound healing. Longitudinal analysis of healing in the 
mouse ear allowed for capture of vessel dynamics over time. Similar to larger vessels, 
tortuous microvessel frequency increased and then gradually decreased relative to normal 
capillaries in the wound site. High-resolution imaging in vivo revealed that endothelial cells 
comprising tortuous microvessels have aberrant cell shapes and suggest altered flow 
dynamics. Surprisingly, tortuous microvessels have increased sprouting compared to normal 
capillaries, indicating for the first time that tortuous vessels contribute to sprouting 
angiogenesis during wound healing. Thus, we identify a new type of tortuous vessel that 
forms from the smallest capillaries and contributes significantly to sprouting angiogenesis in 
wounds. Due to its exuberant sprouting, this class of vessel may be a novel interventional 
target for improved wound healing.  
 
 
3.3 Material and Methods 
Mouse Strains 
All experiments involving animals were performed with approval of the University of 
North Carolina, Chapel Hill Institutional Animal Care and Use Committee. Flk1-GFP mice 
[Kdrtm2.1Jrt/J, JAX #017006] express GFP in endothelial cells as previously described [21]. 
R26R tdTomato [Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J, JAX #007914] mice have a STOP 
cassette flanked by loxP sites followed by tdTomato [22]. Cdh5(PAC)-CreERT2 transgenic 
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mice were generated by microinjecting a transgene containing a genomic Cdh5(PAC) 
promoter fragment fused to a CreERT2 cDNA into zygotes [23]. Cre was induced by one 
application (7 days prior to biopsy punch) of a 10nM solution of tamoxifen dissolved in 
DMSO to the mouse ear for 10 min, then rinsing with ethanol. 
 
Intravital Imaging 
Flk1-GFP mice were commercially obtained from Jackson Laboratory and bred into a 
CD1 background. Mice were anesthetized using 2% isoflurane and a 0.35mm biopsy punch 
(Fine Science Tools) was used to create a small wound. To perform intravital imaging, we 
adhered to a protocol established by Chan et al. [24]. Briefly, mice were placed in an 
induction chamber, anesthetized with 3-4% isoflurane, and then placed on a heating pad with 
continuous 2% isoflurane inhalation. Multiphoton imaging was performed on an Olympus 
FV1000MPE microscope mounted on an upright BX-61WI microscope, using a 25x 
objective, with a custom-built aluminum clamp to immobilize the ear during imaging. A 
coupling gel composed of 300 mM D-sorbitol (Sigma-Aldrich) and 0.5% Carbomer 940 
(Spectrum Chemical) adjusted to pH 7.4, was placed between the objective and coverslip. 
We used a 910nm excitation wavelength to image GFP, and a 960nm excitation wavelength 
to simultaneously image GFP and tdTomato. Images were obtained using the Multi Area 
Time Lapse tool on the Olympus Fluoview software in a 5x5 grid (~1.5mm x 1.5mm) of the 
wound and the surrounding area. Images were processed using Fiji and were stitched together 







To calculate tortuosity index, a modified equation from Bullitt et al. [25] was used. 
We measured the ratio between the shortest distance of the start and end point of a vessel 
segment, noted as the geodesic distance (LG), over the total distance of a vessel segment, 
noted as Euclidian distance (LE). We then multiplied this ratio by the number of inflection 
points, or the number of times the vessel changes direction with a degree of < 1600 (NC). 
Statistical significance was quantified using GraphPad Prism software and an unpaired t-test 
where p<0.05 was significant. To determine the cut-off value for tortuosity, a receiver 
operating characteristic (ROC) curve was used to calculate 3.2 as the value where there is 
100% specificity and 94% sensitivity 
 
In Vivo Flow Experiments 
To visualize in vivo blood flow, we injected 0.1 µm, red fluorescent, FluoSpheres® 
Carboxylate-Modified Microspheres (Invitrogen). Mice were anesthetized with 3% 
isoflurane and a tail vein catheter was used to administer a solution of 10% microspheres in 
sterile PBS. To simultaneously image GFP and red spheres, an excitation wavelength of 
960nm was used. For live capture, we imaged using an Olympus FV1000MPE microscope 
and acquired images at frame rate of 1.1 frames/sec using a 25x objective. Images were 
processed using Fiji. 
 
Antibody Staining 
Mice were euthanized and perfused with 4% PFA. Ears were removed and dissected 
to expose vessels and fixed an additional 2 hr with 4% PFA. Tissue was then rinsed with 
PBS, permeabilized with a 1% Triton X-100/PBS solution for 1hr, then blocked overnight 
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with 5% Serum/0.5% Triton X-100/1% BSA/ PBS (blocking solution). Tissue was incubated 
with PECAM antibody (BD Biosciences) in blocking solution at a 1:100 dilution, overnight 
at 40C. The samples were rinsed with PBS, incubated with Alexa-Fluor 555 secondary 
antibody for 2hr, then rinsed with PBS and mounted onto slides using Vectashield Hard Set 
Mounting Media (Vectashield). Images were acquired on an Olympus FV1200 using a 40x 
objective and processed using Fiji. 
 
Vessel Length and Sprout Analysis 
Vessels segments were traced and isolated using a mask function in Fiji. Tracings 
were skeletonized using the skeletonize plugin in Fiji and analyzed using the Analyze 
Skeleton Plugin in Fiji. Total traced segments were used to determine the percentages of 
tortuous microvessels and normal capillaries for each time point. For sprouting, images were 
stacked to make a time series. The Cell Counter Plugin was used to annotate sprout 
initiations, connections, and retractions from normal and tortuous sprouts. Significance was 




Tortuous Microvessels Are Associated with Wound Healing 
To better understand the role of angiogenesis in wound healing, we investigated this 
process in a mouse ear wound healing model. We employed a Flk1-GFP vascular reporter 
line [21] and a small ear punch biopsy (0.35mm) to induce a wound, and we examined 
angiogenesis and tortuous vessel formation as the wound healed. Using intravital imaging 
and two-photon microscopy, we acquired high-resolution images (including the Z-plane) of 
small caliber vessels growing into the wound site of the same mouse ear over an extended 
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time period (up to 39 days post wounding, dpw) (Figure 3.1A-C; Supplementary Figure 
3.1). Image analysis revealed that small caliber tortuous vessels, which we termed tortuous 
microvessels, were present in the wound area as early as 3dpw, alongside normal small 
capillaries (Figure 3.1D-I).  
We defined a tortuous microvessel as having a diameter of 5-20 µm and oscillating S-
curves, kinks, bends, or twists. To accurately quantify tortuous microvessels during wound 
healing, we applied a tortuosity index (TI) to vessel segments and found that TI values for 
tortuous microvessels were significantly higher than those for normal nearby microvessels in 
the wound, verifying that this vessel type has a distinct morphology that can be quantified 
(Supplementary Figure 3.2A-C). Tracing and binning of all microvessels in the images 
revealed that the total length of microvessels significantly increased from 3dpw to 17dpw, 
coinciding with the angiogenic phase of wound healing, then leveled off during subsequent 
times (Supplementary Figure 3.2D). The percentage of tortuous microvessels also followed 
this time course initially and peaked at 17dpw; however, tortuous microvessels then 
significantly decreased as healing progressed (Figure 3.1J). Comparison of start, peak, and 
end points showed that the percentage increase in tortuous microvessels was significant at 
17dpw compared to the beginning and end of the imaging time (Figure 3.1K). Thus tortuous 
microvessel formation increased inititally as part of the overall trend, but then decreased 
while overall microvessel length stabilized, suggesting that tortuous microvessels resolve 
into normal capillaries over time.  
To more closely examine the relationship between tortuous microvessels and wound 
closure, we measured microvessel location relative to the wound. Circular regions were 
outlined every 100 µm outward from the wound center and used to calculate the percentage 
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of tortuous microvessels in these regions at each time point (Figure 3.2A). We found that the 
majority of vessels near the wound boundary (100-300 µm from centroid) were tortuous 
(Figure 3.2B). Because most tortuous microvessels were found close to the wound boundary, 
we next asked how tortuous microvessels formed in new tissue that is initially avascular. We 
outlined the avascular area (including the biopsy punch hole) around the wound at 1dpw, and 
used this constant area to assess new angiogenesis at subsequent time points (Figure 3.2C, 
Supplementary Figure 3.3A-B). The area remained avascular until 5dpw, and subsequent 
vascularization consisted mainly of tortuous microvessels at early time points (7-17dpw) 
(Figure 3.2D). However, as the wound remodeled, the total length of the tortuous 
microvessels decreased while the total length of the normal capillaries in this area increased, 
and the two lengths were equal by 31-39 dpw. To determine if the predominant 
vascularization by tortuous microvessels at the early time points was due to angiogenesis, 
tissue migration into the wound area, or a combination of both, we tracked the location of 
distinct vessels in this region over time. We found that the wound area initially showed some 
mass movement, suggesting that microvessels may move in due to larger tissue displacement 
at early time points (Supplementary Figure 3.3). However, we tracked individual patterns 
over time and found that, starting around 7-9dpw, mass movement was minimal and new 
microvessels appeared to form via sprouting angiogenesis into the avascular region 
(Supplementary Figure 3.3B). These findings suggest that sprouting angiogenesis is the 
driving force behind vascularization of new tissue after a short burst of tissue displacement, 




We next hypothesized that the shift from tortuous to normal microvessels in the 
avascular area resulted at least in part from resolution of tortuous vessels, and we temporally 
tracked individual tortuous microvessels over time to test this hypothesis (Figure 3.2E-F). 
We found that 69% of tortuous microvessels normalized, while 27% of microvessels 
remained tortuous over the time course of wound healing, suggesting that tortuous 
microvessel formation and resolution is a dynamic process associated with the angiogenic 
phase of wound healing.  
 
Tortuous Microvessel Endothelial Cells have Distinct Properties  
We took advantage of high-resolution intravital imaging to interrogate the endothelial 
cells that line tortuous microvessels. The topology of tortuous microvessels suggested that, 
similar to larger tortuous vessels, they experience disturbed flow, and as a result, the 
endothelial cells may change shape and acquire other properties consistent with a state of 
“activation” [26]. We acquired images from live intravital imaging while injecting small-
diameter fluorescent microspheres to visualize blood flow. Before injection, there were no 
red fluorescent microspheres present in any vessels (Figure 3.3A). Upon injection, the 
microspheres moved through the imaging field quickly in areas with linear capillaries, and 
microsphere patterns changed completely from one time frame to the next (Figure 3.3B-F, 
blue boxes). In contrast, some microspheres appeared to “stick” in the curved area of tortuous 
microvessels, and these became more prevalent with time (Figure 3.3B-G, red boxes), while 
the linear regions lost association with microspheres over time as they were presumably 
cleared from the circulation. Analysis revealed that on average 5 beads per tortuous 
microvessel remained stationary post-injection, while no beads were stationary in linear 
microvessels (Figure 3.3H). These findings indicate that endothelial cells in tortuous 
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microvessels differ from those in linear regions, and suggest that reduced or disturbed blood 
flow is associated with tortuous microvessels, which could ultimately lead to differences in 
endothelial cell properties between normal and tortuous microvessels. 
Since activated endothelial cells are often round rather than being spindle-shaped and 
elongated, we hypothesized that endothelial cells in tortuous microvessels had abnormal cell 
shapes. To test this hypothesis, we generated mosaic mouse lines that expressed GFP in 
endothelial cells along with a vascular-selective inducible Cre driver, Cdh5-CreERT2 [23], 
and a tdTomato excision reporter [22]. The reporter was activated in a small subset of 
endothelial cells (10-30%) using low-dose tamoxifen prior to wound healing, and individual 
groups of endothelial cells were followed over the wound healing time course. Endothelial 
cells in normal capillaries maintained a stereotypical spindle shape, while those in tortuous 
microvessels were spindle-shaped at 1dpw, but became more rounded over time, coincident 
with increased tortuosity (Figure 3.4A-B). The shapes of individual endothelial cells were 
measured at 11dpw in fixed samples stained for PECAM-1, an endothelial cell border marker 
(Figure 3.4C). The longitudinal/transverse axis ratio was significantly reduced in endothelial 
cells from tortuous microvessels relative to control endothelial cells in normal microvessels 
(Figure 3.4D). These data confirm the visual appearance of endothelial cells in tortuous 
microvessels as rounded and suggestive of “activation”.  Taken together, these results show 
that endothelial cells in tortuous microvessels behave abnormally by several criteria.  
 
Tortuous Microvessels Sprout Robustly 
The altered morphology and properties of tortuous microvessel endothelial cells 
suggest that they are more “activated” than endothelial cells in normal capillaries, and 
activation is often associated with sprouting. Thus we hypothesized that tortuous microvessel 
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endothelial cells sprout more frequently than normal capillaries, and we used our high-
resolution longitudinal dataset of wound healing angiogenesis to test this idea. Analysis of 
blood vessel sprouts, defined as new extensions of at least 10µm that were unconnected 
(blind-ended) and that initiated during the wound healing time course, revealed that tortuous 
microvessels sprouted exuberantly (Figure 3.5A-G). For example, a microvessel near the 
wound that appeared normal at 1dpw subsequently became tortuous at 5dpw, and sprouts 
emanated from curved regions (Figure 3.5A-B). At 7dpw, the main microvessel remained 
tortuous, and the sprouts continued to extend (Figure 3.5C). By 9dpw onward, the main 
microvessel began to normalize, while the sprouts persisted and made connections to each 
other or to other vessels (Figure 3.5D-F). When analyzing new sprout initiations, we found 
that tortuous microvessels sprouted at a significantly higher frequency than normal 
capillaries from 5-13dpw (Figure 3.5G).  
To determine if sprout initiations from tortuous microvessels were more or less stable 
than sprout initiations from normal vessels, we quantified how often sprouts from each type 
of vessel formed a connection or retraction (Supplementary Figure 3.4A-B). Our analysis 
showed no significant differences between connections and retractions of sprouts from 
tortuous or normal microvessels (Supplementary Figure 3.4C), suggesting that sprouting 
from tortuous vessels leads to stable connections and expand the vascular plexus near the 
wound site. We asked whether sprouting from tortuous microvessels was a resolution 
mechanism, and found that 36% of tortuous microvessels normalized after sprouting while 
54% normalized without sprouting, suggesting that sprouting is not required for vessel 
normalization (Supplementary Figure 3.4D). 
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To better understand the sprouting behavior of tortuous microvessels, we examined 
when sprout initiations occurred relative to acquisition of microvessel tortuosity (Figure 
3.5H-L). This analysis showed that significantly more sprouts formed after microvessels 
became tortuous compared to sprouts initiating co-incident with tortuosity (Figure 3.5L), 
suggesting that sprouting is downstream of tortuous vessel formation. This data suggests that 
endothelial cells remain inactive and less likely to sprout absent tortuosity. To determine if 
there were regions within tortuous microvessels that were more “active,” we measured sprout 
initiations from curved regions vs. non-curved regions of tortuous microvessels. Our data 
revealed a significant increase in sprout frequency from the apex of the curved region of 
tortuous microvessels vs. other areas of the vessel (Figure 3.5M-O), suggesting that these 
curved areas are the most active regions of tortuous microvessels. Taken together, these data 
support our hypothesis that endothelial cells in tortuous microvessels are distinct and perhaps 
activated, and the enhanced sprouting frequency combined with enhanced overall tortuosity 
suggest that tortuous microvessel formation is a key player during the angiogenic phase of 
wound healing.  
 
3.5 Discussion 
Here we identify tortuous microvessels for the first time, and present a longitudinal, 
in-depth analysis of microvessel tortuosity during wound healing. Microvessel tortuosity 
increases over a reproducible time course that largely correlates with increased overall 
angiogenesis. We show that sprouting is promoted from tortuous microvessels, and this 
exuberant sprouting likely contributes significantly to wound angiogenesis and overall 
healing. Our data is consistent with a model whereby tortuosity alters flow parameters and 
leads to endothelial cell activation that promotes sprouting in these regions (Figure 3.5P). 
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Thus, the emergence of tortuous microvessels near a wound site may be a mechanism to 
efficiently expand wound angiogenesis and promote healing. 
Although tortuous vessels have been observed during wound healing and in diseases 
such as cancer [13, 27], microvessels of the caliber (5-20um) analyzed here were not 
resolved by most of these studies. Yet the bulk of the vasculature in most vessel beds is 
comprised of small caliber capillaries, and these capillaries are usually the source of sprouts 
that contribute to neo-angiogenesis. While some studies analyzed static images of wound 
vessels [13, 28, 29], our approach allowed for high spatio-temporal resolution of 
microvessels and longitudinal analysis of this critical component of wound healing. Our 
finding that tortuous microvessels contribute significantly to overall sprouting angiogenesis 
in the wound environment, and our results showing that these sprouts often lead to new 
connections and conduits, provide a novel link between vessel tortuosity and wound healing 
via sprouting angiogenesis.  
Sprouting from tortuous microvessels occurs at a higher frequency than from normal 
vessels, and these sprouts often initiate from the apex of curved regions of tortuous 
microvessels. While we don’t have the resolution to interrogate junctional integrity, our 
finding that microspheres become “stuck” in the tortuous microvessels suggests altered blood 
flow and shear stress. Interestingly, a recent study by Ghafarri et al. showed that sprouts 
emanate from the lowest minimum in predicted shear stress along a capillary network, 
indicating that reduced shear stress promotes sprouting events [30]. Given these results, and 
our live-capture of circulating microspheres, we predict that shear stress is lower and/or 
disturbed in tortuous microvessels relative to normal capillaries downstream of altered vessel 
morphology. The altered shape of endothelial cells within tortuous microvessels is consistent 
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with this idea, since relative loss of the laminar flow vector is predicted to loosen junctions, 
“activate” endothelial cells, and promote sprouting. Likewise, the enhanced sprout initiations 
we observed from the apex of curved regions suggest that altered flow may induce local 
discontinuities that are optimized for sprouting in those regions.  
What triggers tortuous microvessel formation during wound healing? It is likely a 
complex combination of local environmental cues and other changes associated with wound 
healing, since the tortuous microvessels resolve over time. The peak frequency of tortuous 
microvessels roughly corresponds to the “angiogenic phase” of wound healing [14], and it is 
known that pro-angiogenic cytokines such as VEGF induce tortuosity [15, 27, 31]. Tortuous 
microvessels are enriched close to the wound border, which is the most hypoxic area of the 
wound, consistent with pro-angiogenic influences. However, pro-angiogenic signals are not 
sufficient to induce vessel tortuosity since most developmental angiogenesis occurs 
independent of tortuosity. Wound healing is also associated with transient inflammation, so 
pro-inflammatory cytokines may also contribute to microvessel tortuosity. In any case, it is 
likely that local changes in the wound healing environment promote tortuosity, and this work 
shows that vessel tortuosity contributes substantially to microvessel sprouting and neo-
angiogenesis that promotes wound healing.    
The wound healing process is a natural physiological response, but wound healing is 
compromised in some diseases as a result of defective vascularization. For example, wound 
healing is often defective in diabetic patients and sometimes results in limb amputation, and a 
defective angiogenic response from the microcirculation contributes to this dysfunction [32, 
33].The microcirculation is comprised of capillaries that make up the bulk of the vasculature 
and readily respond to signaling cues. Here, we identify a new class of vessel, a tortuous 
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microvessel, that is associated with wound healing and contributes significant angiogenic 
sprouting to the process. Knowledge of the contribution of tortuous microvessels to 
angiogenic sprouting and wound healing will be useful in thinking of new therapeutic 










Figure 3.1. Tortuous microvessels during wound healing.  
(A-C) Wound and surrounding vasculature at indicated times. Yellow stippled line, wound 
punch and avascular area; boxes, areas magnified below. (D-F) High magnification of blue 
boxed areas showing normal microvessels. (G-I) High magnification of red boxed areas 
showing tortuous microvessels. (J) Quantification of percentage of tortuous microvessels 
over time, n=3 ears. (K) Graph representing the ratio of tortuous to normal microvessels at 
indicated times, n= 3 ears. Error bars, mean + SEM; Statistical comparisons by Two-Way 
ANOVA with Tukey’s Multiple Comparison Test; *, p≤0.05; ****, p≤0.0005. Scale bars: 





Figure 3.2. Tortuous microvessel location, formation, and resolution.  
(A) Example of 3dpw wound illustrating defined regions every 100 µm (not to scale). Note 
avascular area (wound punch + tissue) in segments close to the wound. (B) Dot plot 
representing percentage of tortuous microvessels in each region over time. Warmer colors 
(red/orange), elevated tortuous microvessels; cooler colors (blue/purple), reduced tortuous 
microvessels. (C) Avascular wound area + punch, defined at 1dpw and analyzed at 
subsequent time points. (D) Quantification of normal and tortuous microvessel length in new 
wound tissue (same areas measured for all time points). Error bars, mean + SEM. Statistical 
comparisons, Two-Way ANOVA with Sidak's Multiple Comparisons test. *, p≤0.05, 
**p≤0.005. (E) Example of a tortuous microvessel over time, showing normalization. (F) 
Percentage of vessels that normalized, remained tortuous, or outcome unknown during 39 
day wound healing time course. n=86 tortuous microvessels. Vessels pseudo colored using 





Figure 3.3. Circulating microspheres accumulate in tortuous microvessels.  
Representative images from movie of circulating microspheres; time (T) sec, upper right. (A) 
Prior to injection of microspheres into tail vein. (B-F) Images post-injection at indicated 
times. Blue insets, linear microvessel; red insets, tortuous microvessel; yellow arrowheads, 
microspheres stationary for multiple time frames. Note that no microspheres remain in the 
normal vessel segment (blue inset) as opposed to trapped microspheres in the tortuous 
microvessel (arrows in red inset). (G) Illustration showing tortuous microvessel and areas 
where microspheres became trapped. (H) Quantification of microsphere trapping in normal 
and tortuous microvessels; long line and error bars, mean +/- SEM. Statistical comparisons, 





Figure 3.4. Cellular morphology in tortuous microvessels.  
Mosaic analysis of microvessels during wound healing in mice of indicated genotype. (A) 
Normal microvessel EC have stereotypical spindle morphology throughout time course (blue 
arrowheads, red cell in diagram). (B) Tortuous microvessel EC initiate as spindle-like and 
become rounded with time and tortuosity (blue arrowheads, red cell in diagram). (C) 
PECAM staining of Flk1-GFP mice at 11dpw highlighting individual cell borders. (D) Ratio 
of longitudinal to transverse axis of EC in normal and tortuous microvessels; long line and 
error bars, mean +/- SEM. Statistical comparisons, Students t-test (unpaired, two-tailed); 





Figure 3.5. Tortuous microvessels have increased sprouting.  
(A-F) Example of a normal microvessel near wound that became tortuous and initiated 
sprouting. (A) Normal microvessel near wound at 1dpw. (B) At 5dpw, the main microvessel 
became tortuous and initiated sprouting (blue arrows) from the apex of curved regions 
(yellow arrowheads). (C) Main microvessel remained tortuous and sprouts persisted at 7dpw. 
(D-F) From 9-15dpw, the main tortuous microvessel was normalized and the sprouts formed 
new connections (green arrows). (G) Quantification of sprout initiations from normal and 
tortuous microvessels during wound healing, n=3 ears. Error bars, mean + SEM; Statistical 
comparisons: Two Way ANOVA with Sidak’s Multiple Comparisons Test. *, p≤0.05; **, 
p≤0.005; ****, p≤0.0005. (H-K) Example of sprout initiation after tortuous microvessel 
formation. Note that sprout initiation does not occur until 9dpw (K, yellow arrow). (L) 
Quantification of sprout initiations subsequent to tortuous microvessel formation relative to 
sprout initiations simultaneous with tortuous microvessel formation. Error bars, mean + 
SEM; Statistical comparisons: Students t-test (unpaired, two-tailed); **, p≤0.005. (M) 
Example of sprout initiation from apex of curve on tortuous microvessel. (N) Example of 
sprout initiation from non-curved region of tortuous microvessel. (O) Quantification of 
sprout initiations from the apex of tortuous microvessels relative to non-curved regions. Error 
bars, mean + SEM; Statistical comparisons: Students t-test (unpaired, two-tailed); **, 
p≤0.005. (P) Model of tortuous microvessel initiation, sprouting, and resolution during 






Supplementary Figure 3.1. Time course for wound healing in mouse ear.  
Wound incurred at 0dpw. Z-stack image frames of wound area expressing Flk-GFP 
(vascular, white) were stitched together for each time point and used for analysis. Yellow 





Supplementary Figure 3.2. Tortuosity index.  
(A-B) Example of a normal microvessel segment (A) or tortuous microvessel segment (B), 
highlighting the geodesic distance (LG, pink line), the Euclidean distance (LE, blue line) and 
the number of inflection points (yellow stars). Note increased number of inflection points in 
tortuous vs. normal microvessel segment. On top is the equation used to calculate the 
tortuosity index (TI). (C) Quantification of TI values for normal and tortuous microvessel 
segments. Line and error bars, mean +/- SEM. Statistical comparisons: Students t-test 
(unpaired, two-tailed); ****, p≤0.0001. (D) Quantification of total microvessel length 





Supplementary Figure 3.3. The avascular area of the wound.  
(A) Avascular area + wound punch outlined at 1dpw and used to analyze subsequent time 
points. (B) Defined 1 dpw area at subsequent time points. Segments pseudo colored with 





Supplementary Figure 3.4. Comparison of sprout dynamics.  
(A) Example of sprout initiation from a tortuous microvessel (yellow arrow) that connected 
to another vessel segment (blue vessel). (B) Example of a sprout initiation from a tortuous 
microvessel (yellow arrow) that retracted. (C) Percentage of sprout initiations from normal 
(blue) or tortuous (red) microvessels that resulted in connections or retractions. (D) 
Percentage of tortuous microvessels that exhibited sprouting and normalized (blue), exhibited 
sprouting and did not normalize (red), or normalized absent sprouting (yellow). Vessels 
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Chapter 4: General Discussion 
 
4.1 Endothelial deletion of BMPR2 decreases sprouting during retinal development 
BMP signaling increases sprouting angiogenesis and vascular branching in the 
developing retina. Here, we showed that BMP2,4,6,7 ligands are found in the retina from P1-
P6 and that the BMP receptors, ALK1, ALK2, ALK3, and BMPR2 are enriched in blood 
vessels of the retina. Endothelial specific deletion of Bmpr2, Alk2, and Alk3 resulted in 
decreased sprouting at the vascular front and decreased branching in the plexus while 
deletion of Alk1 resulted in increased branching. These results indicate that BMP signaling is 
not required to initiate angiogenesis, but is required for expansion of the network and 
maintenance.  
Previously, BMP signaling has been implicated as being a pro-angiogenic cue for 
ectopic sprouting from veins. Wiley et al. showed that overexpressing the bmp2b ligand in 
zebrafish resulted in increased sprouting from only the venous compartment [1]. 
Interestingly, we did not find that BMP expression or activity was restricted to veins in the 
postnatal mouse retina. We found that BMP receptors were pan-endothelial, suggesting that 
manipulating BMP signaling would not be restricted to a vessel type in this vascular bed. A 
recent study shows that the ability of endothelial cells to sprout in response to BMP is 
correlated to the level of Notch activity in individual cells [2]. When Notch activity is high, 
endothelial cells do not sprout in response to BMP overexpression. In zebrafish, Notch 
signaling is robust in the dorsal aorta, inhibiting cells from the aorta to be able to respond to 
96 
 
BMP. In contrast, Notch activity is low in the postnatal retina [3]. From P3-P5, Notch 
activity is present in sporadic cells and is not robustly present in the arteries over veins. Thus, 
since Notch activity is low in the retina, it is possible that Notch signaling is not a limiting 
factor in BMP responsiveness in the postnatal retina. This explains why we did not observe 
changes in sprouting frequency from specific vessel types; instead, sprouting was affected in 
all vessel types. 
 Although most BMP signaling components have been shown to be pro-angiogenic 
during development [4], the interaction between BMP9/BMP10 and receptor, Alk1, has been 
shown to have an anti-angiogenic role. Here, we found that endothelial specific deletion of 
the Alk1 receptor resulted in increased vascular density, consistent with an anti-angiogenic 
effect. However, of note is the fact that there is little BMP9 and BMP10 mRNA in the retina, 
so why is there an effect when Alk1 is knocked down? It has been reported that BMP9 and 
BMP10 ligands are mainly found in circulation and that the amounts of these ligands are 
higher during birth than in adulthood [5]. Thus, examining mRNA in the retina could be 
misrepresenting the physiological levels of BMP9/10 and their effect on angiogenesis. Since 
there was significantly increased vessel density with the endothelial specific knock-out of 
Alk1, we can predict that BMP9 and BMP10 are active in the retina, even if the ligands are 
not being produced in the retina.  
 We showed that the ALK3/BMPR2 signaling axis provides a stronger contribution to 
sprouting at the vascular front, compared to ALK2/BMPR2 which has a stronger effect on 
vascular branching behind the vascular front. The stronger effects of Alk3 on sprouting could 
be due to the presence of Alk3 on filopodia tips. Pi et al showed that ALK6 translocates to 
filopodial tips after BMP6 stimulation [6]. Since ALK3 and ALK6 share structural homology 
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(85% in their kinase domain and 42% in the extracellular domain) and BMP6 binds 
preferentially to ALK3 over ALK6 [7], it is possible that ALK3 is also present at the tips of 
filopodia and is aiding in sprout guidance. The presence of ALK3 at filopodia tips would 
explain the different phenotypes observed between endothelial specific deletion of Alk2 and 
Alk3. 
   
4.2 Tortuous vessels exhibit unique properties and increased sprouting angiogenesis 
 Tortuous vessels are abnormal vessels associated with wound healing and disease. 
The causes and consequences of tortuous vessels remain understudied. Here, we provided an 
in-depth analysis of tortuous microvessels during wound healing. We showed that tortuous 
vessels form through sprouting angiogenesis and resolve by becoming normal vessels. By 
imaging microbeads in circulation, we predict flow differences between normal and tortuous 
vessels, possibly leading to activation of endothelial cells within tortuous vessels and causing 
them to sprout robustly. 
 A question that remains unanswered is, why are tortuous vessels present in the wound 
in the first place? Our data shows that tortuous microvessels sprout at a higher frequency 
than normal vessels, increasing the vessel density near the wound. Previous reports have 
stated that the vessel density can be up to 10x the normal amount after a wound is made [8]. 
A mechanism in which vessels are able to grow and sprout rapidly is needed to account for 
the exponential growth, and tortuous microvessel formation and sprouting could be the 
answer to rapid expansion of the vascular network. Additionally, tortuous microvessels are 
leakier than normal vessels (data not shown), suggesting increased extravasation of solutes to 
the wound area, thereby increasing the rate of healing. Thus, the role of tortuous vessels near 
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the wound could be for rapid expansion of the vessel network allowing for increased solute 
and immune cell transport and secretion to the wound site.   
 One idea on how tortuous vessels form centers on the effect of changes to 
extracellular matrix on vessel morphology. Multiple studies, including genetic KO mouse 
models, have shown that providing an unsupportive matrix environment can lead to 
tortuosity [9]. When surrounding connective tissue degrades or is not stiff enough to support 
the vessel, tortuosity can occur [10]. Mice lacking the elastin component, FIBULIN5, 
developed tortuous arteries due to decreased elastic fibers that cannot fully support arteries 
[11]. Additionally, continuously stretching rat ears by applying a constant tensile force can 
change the viscoelastic properties, stimulating cell proliferation and vessel remodeling, 
ultimately resulting in tortuous vessels [12]. Skin stretching elevated expression of HIF-1α 
and VEGF, but had minimal effects on the inflammatory response. Taken together, this data 
suggests that the tortuous microvessels I observed during wound healing can be attributed to 
changes in the ECM associated with wound healing. Although I am able to visualize collagen 
I fibers using second harmonics generated by two-photon excitation [13], I did not observe 
any obvious changes in collagen deposition during wound healing. In fact, the collagen 
matrix was behind the leading vascular front, where most tortuous microvessels are formed. 
However, this does not rule out the possibility of other matrix components contributing to 
tortuous microvessel formation, such as collagen IV. Collagen IV is a basement membrane 
component that significantly contributes to vessel elongation, proliferation, and stabilization, 




We observed that tortuosity “activates” endothelial cells and is upstream of sprout 
initiations. Even though multiphoton intravital imaging has been around for a few decades 
[15], sprouting from tortuous vessels has not been previously documented, to our knowledge. 
Yet, one intravital imaging study that focused on the tumor microvasculature noted the 
presence of tortuous vessels and sprouting [16]. Manning et al. found that vascular margins 
existed around a tumor with varying degrees of vessel tortuosity. Although they showed one 
example of a sprouting event near the tumor, they noted that the tortuous vessel became 
linear before the sprout was observed. Considering tumors and wounds have similar 
microenvironments [17], it is surprising that the authors did not observe sprouting from 
tortuous microvessels. One explanation for this inconsistency is that the authors were not 
actively looking for sprouting events and could have missed sprout initiations from tortuous 
vessels. Yet another explanation is that a vascular front does not exist in tumor angiogenesis, 
so it may be difficult to visualize sprout initiations at the same capacity as wound healing, 
where the vascular front encapsulates the wounded tissue.  
My studies have uncovered a new characteristic of tortuosity, sprouting, that can be 
used as a target for tortuous vessel normalization or anti-angiogenic therapies. Understanding 
the differences between normal and tortuous vessels and how tortuous vessels form and 
resolve during wound healing are key to unlocking mechanisms to combat cancer. 
  
4.3 Tortuous vessel normalization to combat disease 
 Tortuous vessels are observed in many diseases, ranging from cancer and diabetes to 
atherosclerosis and hypertension [10]. Even though tortuous vessels can be used as a 
prognostic marker for these diseases, the outcome on vessel density can vary. For example, 
100 
 
the tumor environment promotes vessel growth whereas diabetes promotes ischemia and 
inhibits vascular growth. Therefore, careful consideration for the disease mechanisms and 
their impact on angiogenesis must be taken when trying to find a suitable therapy. 
Studies pioneered by Dr. Judah Folkman revealed that angiogenesis is a major 
contributor of tumor growth and that tumors secrete factors that attract blood vessels [18]. 
Since his initial observations almost 50 years ago, cancer therapies are still aimed at targeting 
the tumor microvasculature to inhibit tumor growth and metastasis. Mostly, anti-angiogenic 
therapies have been used in conjunction with chemotherapy to decrease proliferating 
endothelial cells [19, 20], however this treatment has not been completely effective and the 
endothelial cells that escape and repopulate the tumor environment become resistant to anti-
angiogenic drugs and exhibit increased virulence [21, 22]. More recently, a new concept has 
emerged that focuses on normalizing the tortuous vessels in the tumor microenvironment, i.e. 
making the vessels less leaky, to increase the efficiency of cancer drugs reaching their target 
[23]. Normalizing abnormal tumor vessels in a breast cancer mouse model enhanced the 
efficacy of an anticancer vaccine therapy [24], providing credibility to this new hypothesis.  
Since tortuous vessels naturally resolve after a wound is healed, the mechanisms that lead to 
abnormal vessel normalization can be deciphered from further in depth studies of tortuous 
microvessels and wound healing. Finding biomarkers that distinguish normal and tortuous 
vessels would be ideal in performing RNA-seq between the two different endothelial 
populations during the different phases of wound healing. The results from this experiment 
could unravel the important mechanisms involved in tortuous vessel resolution. Based on my 
studies and the literature, I predict that genes that are upregulated during inflammation, such 
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as Vcam-1 and Icam-1, are also increased in tortuous endothelial cells. Thus, reducing the 
inflammatory response may be a key factor in tumor vessel normalization.  
Not all tortuous vessels share the same properties. Collateral vessels are small vessels 
that do not experience flow under normal circumstances. In the event of an arterial occlusion, 
the surrounding collateral arteries are used to bypass the occlusion and maintain proper 
circulation [25]. It is not known whether collateral tortuosity is present before flow and 
predetermined by spatial restrictions or whether the onset of flow in collaterals induces 
tortuosity. However, since the main function of these arteries is to maintain flow, 
permeability in these vessels would not be favorable. A comparison between tortuous 
collateral arteries and wound-associated tortuous microvessels would reveal additional 
mechanisms that regulate permeability. In the tumor microenvironment, leaky tortuous 
vessels do not allow efficient drug penetration to the tumor [26]. Therefore, making tortuous 
vessels less permeable would increase dose delivery of anti-cancer drugs to the tumor, 
making current cancer therapies more effective. 
I have argued that increased angiogenesis during wound healing is advantageous, 
however excessive angiogenesis can lead to increased scarring [8, 27]. In fetal and oral 
mucosa wounds, there is a decreased inflammatory response and angiogenesis, resulting in 
reduced scar formation [28, 29]. One idea is that apoptosis of endothelial cells during the 
remodeling phase contributes to the scar tissue [8]. Anti-angiogenic drugs applied to wounds 
lead to normal wound closure suggesting that the angiogenic response during wound healing 
is excessive, unnecessary, and increases scarring. Thus, since tortuous microvessels sprout 
robustly and increase vessel density near the wound, normalizing tortuosity during wound 
healing can decrease angiogenesis and vessel density, leading to decreased scarring. 
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Although this would be beneficial from a cosmetic point of view, it is important to keep in 
mind that not all wounds have excessive angiogenesis. Diabetic wounds have decreased 
vascularization and ischemia, therefore treating diabetic wounds with anti-angiogenic drugs 
would not be recommended. 
 
4.4 Summary 
 In conclusion, I have emphasized the importance of BMP signaling during 
developmental angiogenesis and highlighted the complexities of the signaling pathway. 
Additional genetic manipulation of the different ligands and receptors will further elucidate 
any additional roles BMP has on angiogenesis. I have also provided an in-depth discussion of 
tortuous vessels and how they can be used as a therapeutic target. Further studies into the 
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